Conolidine’s analgesic results stem from its conversation with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors in the central anxious process, conolidine modulates alternate molecular targets. A Science Improvements review observed that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By infl... https://peterq332cau8.lotrlegendswiki.com/user